東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Chemotherapy induced peripheral neur...

Speck, Rebecca M.

FindBook

Google Book

Amazon

博客來

Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact./
作者:	Speck, Rebecca M.
面頁冊數:	87 p.
附註:	Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.
Contained By:	Dissertation Abstracts International74-06B(E).
標題:	Health Sciences, Epidemiology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3551772
ISBN:	9781267898630

Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact.
Speck, Rebecca M.

Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact. - 87 p.

Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.

Thesis (Ph.D.)--University of Pennsylvania, 2012.

Chemotherapy induced peripheral neuropathy (CIPN) is an adverse effect of taxane-based chemotherapy, the most frequently used therapy for treating breast cancer. CIPN is a serious burden for patients - affecting quality of life and function potentially to an extent that is dose-limiting. Few options to prevent CIPN have been tested, and treatments have demonstrated limited effectiveness. A better understanding of how patients experience and manage CIPN symptoms may lend insight to their symptom management needs, and measurement of the incidence and risk factors of dose-limiting CIPN will quantify the problem and allow vulnerable patients to be targeted for acceptable tailored interventions and treatments.

ISBN: 9781267898630Subjects--Topical Terms:

1019544
Health Sciences, Epidemiology.

Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact.
LDR:03354nam a2200289 4500 001 1960361
005 20140611111912.5
008 150210s2012 ||||||||||||||||| ||eng d
020 $a 9781267898630
035 $a (MiAaPQ)AAI3551772
035 $a AAI3551772
040 $a MiAaPQ $c MiAaPQ
100 1 $a Speck, Rebecca M. $3 2095999
245 1 0 $a Chemotherapy induced peripheral neuropathy in non-metastatic breast cancer: Patient experience and clinical impact.
300 $a 87 p.
500 $a Source: Dissertation Abstracts International, Volume: 74-06(E), Section: B.
500 $a Advisers: Angela DeMichele; Sean Hennessy.
502 $a Thesis (Ph.D.)--University of Pennsylvania, 2012.
520 $a Chemotherapy induced peripheral neuropathy (CIPN) is an adverse effect of taxane-based chemotherapy, the most frequently used therapy for treating breast cancer. CIPN is a serious burden for patients - affecting quality of life and function potentially to an extent that is dose-limiting. Few options to prevent CIPN have been tested, and treatments have demonstrated limited effectiveness. A better understanding of how patients experience and manage CIPN symptoms may lend insight to their symptom management needs, and measurement of the incidence and risk factors of dose-limiting CIPN will quantify the problem and allow vulnerable patients to be targeted for acceptable tailored interventions and treatments.
520 $a To study the patient experience and clinical impact of CIPN this dissertation involves two projects: (1) a mixed methods study using a purposive sample of 25 breast cancer patients treated with docetaxel or paclitaxel to explore the self-management strategies for coping with CIPN symptoms, and to discriminate the CIPN experience from that of other toxicities; and (2) a retrospective cohort study of 488 women treated with docetaxel or paclitaxel to measure the incidence of treatment modification (TM) events attributed to CIPN (TM-CIPN), and assess whether body mass index (BMI) and body surface area (BSA) are important risk factors given their role in chemotherapy dosing and distribution.
520 $a These two projects demonstrated important findings, advancing our understanding of CIPN. Project one found that CIPN affected routine activities, functions, and behaviors in the areas of domestic, work, and social/leisure life. The self-management strategies reported by women focused on movement to reduce symptoms, attitude awareness, logistics to simplify demands, and environmental change. An unexpected finding of project one was that taste alteration was a commonly experienced side effect. Similarly to CIPN, taste alteration resulted in self-management strategies. Project two found that 50 (10.2%) women had a TM-CIPN, (2.4% with docetaxel and 16.1% with paclitaxel, p<0.001). BMI and BSA were not independently associated with the risk of TM-CIPN; black race was a significant risk factor and important confounder. Future research should assess the effectiveness of reported self-management strategies, and examine factors that may explain black race as a risk factor for dose-limiting CIPN.
590 $a School code: 0175.
650 4 $a Health Sciences, Epidemiology. $3 1019544
690 $a 0766
710 2 $a University of Pennsylvania. $b Epidemiology and Biostatistics. $3 2096000
773 0 $t Dissertation Abstracts International $g 74-06B(E).
790 $a 0175
791 $a Ph.D.
792 $a 2012
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3551772